The Nordic EMBL Partnership for Molecular Medicine will hold its Annual Meeting in September 2020

The 10^th Annual Meeting of the Nordic EMBL Partnership for Molecular Medicine between 22-25 September 2020, is organized by the Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, and it will be a virtual meeting. It brings together mainly the group leaders, postdoctoral researchers, and PhD students of the Nordic EMBL Partnership with researchers from EMBL and its broader network to discuss their research, develop new ideas and initiate new projects.

We are looking forward to sharing an exciting and motivating four days of scientific meeting with you! Please visit the conference website for more information, regarding registration and abstract susmission: https://2020nordicemblpartnership.se/ 

Banner by Umeå Congress.

A high profile review publication on antibiotic resistance from the Hauryliuk and Atkinson labs

Antibiotics bind to and corrupt the functioning of crucial elements of bacterial cells, such as the ribosome that synthesises proteins or RNA polymerase that reads genes to generate mRNA. To counter the action of antibiotics, bacteria have evolved numerous dedicated mechanisms of resistance. Commonly, these resistance mechanisms act by either destroying the antibiotic, pumping it out of the cell or permanently modifying the molecular target so it becomes immune to the antibiotic, e.g. by post-translational modification such as methylation.

In this review published in the influential journal Nature Reviews Microbiology, Umeå researchers Vasili Hauryliuk (also affiliated with Tartu University, Estonia) and Gemma C. Atkinson together with their collaborators Daniel N. Wilson (University of Hamburg, Germany) and Alex J. O’Neill (University of Leeds, UK) discuss an important and increasingly recognised type of antibiotic resistance: antibiotic resistance through target protection.

Read more: A high profile review publication on antibiotic resistance from the Hauryliuk and Atkinson labs

New publication with Vasili Hauryliuk on "Make it or break it: how bacteria balance production and degradation of the ´magic spot´ signaling alarmone"

When stressed or starved, bacteria regulate their metabolism by producing signalling molecules called alarmones or ‘magic spots’. In the majority of bacteria, the magic spot compounds are both made and destroyed by a large, complex enzyme called Rel. The question of how Rel switches from making the alarmone to degrading it was finally resolved by an international team from Sweden – Vasili Hauryliuk (MIMS & UCMR) – and Belgium: Jelle Hendrix (Hasselt University) and Abel Garcia-Pino (Université Libre de Bruxelles). The results of this study were published in the high impact journal Nature Chemical Biology ("A nucleotide-switch mechanism mediates opposing catalytic activities of Rel enzymes", 11 May 2020).

Read more: New publication with Vasili Hauryliuk on "Make it or break it: how bacteria balance production and...

MIMS Clinical Research Fellowships awarded to two virologists

Molecular Infection Medicine Sweden (MIMS) has this week announced the annual winners of its national Clinical Research Fellowship (CRF) program. An international panel of clinical researchers has awarded fellowships to Sara Gredmark Russ at the Karolinska Institute and Anne-Marie Fors Connolly at Umeå University to conduct research into how different viruses infect human cells and cause disease.

Sara Gredmark Russ is a specialist doctor in infectious diseases at Stockholm’s Karolinska University Hospital. Following her medical degree and PhD in experimental medicine at the Karolinska Institute, she conducted research at the Whithead Institute at MIT (USA), before she established her own research group within the area of immunology, focusing on how viruses interact with the human immune system. Dr. Gredmark Russ studies tick-borne encephalitis (TBE), a serious viral infection of the central nervous system caused by tick-borne encephalitis virus (TBEV). Her team will now answer how the virus causes disease. In her fellowship project, she will work with MIMS scientist Anna Överby Wernstedt to identify human host cell factors important for TBE virus infection and replication. Her ultimate aim is to discover novel therapeutic targets to treat TBE, which are urgently required. 

Anne-Marie Fors Connolly is a clinician researcher at the Department of Clinical Microbiology and University Hospital of Umeå. Originally from Denmark, Anne-Marie Fors Connolly earned a PhD from Karolinska Institute in Stockholm, before she completed her medical degree in Umeå. She will establish a translational research group to understand the disease caused by Puumala Orthohantavirus, hemorrhagic fever with renal syndrome (HFRS), known in Sweden as “sorkfeber”. Compared to other hantavirus infections, HFRS is rarely lethal, but Dr. Fors Conolly has previously shown that it is a risk factor, for instance for heart attack and stroke. There are no drugs to eliminate the virus, and the aim now is to identify treatment strategies, which may also point the way for treating other viral hemorrhagic fevers. 

Read more: MIMS Clinical Research Fellowships awarded to two virologists

Vasili Hauryliuk (MIMS) and Gemma Atkinson (UCMR) lead milestone paper in PNAS on new kind of regulatory toxin-antitoxin system

Bacteria use small molecules to slam the brakes on their own growth

An international research team under the lead of scientists at Molecular Infection Medicine Sweden (MIMS) and the Umeå Center for Microbial Research (UCMR) have uncovered a new kind of regulatory system of toxin and antitoxin proteins in bacteria that could be a defense system against viral attack. The bioinformatic identification of the proteins and their experimental validation are now published in the high impact journal Proceedings of the National Academy of Sciences of the US (PNAS, 28 April 2020, entitled "A widespread toxin-antitoxin system exploiting growth control via alarmone signaling").

When bacteria get stressed e.g. through antibiotic treatment or the lack of nutrients, they slow down their growth mechanism by small signaling molecules called Alarmones. The Atkinson and Hauryliuk labs at Umeå University have worked on the proteins that make and degrade alarmones for over a decade. They previously revealed the ubiquitous presence of small proteins that make alarmones, called small alarmone synthetases or SASs, encoded in bacterial genomes.

It was an unanswered question why bacteria carry SAS proteins in addition to their standard tool-set for alarmone synthesis and degradation. Now, Gemma C. Atkinson, Vasili Hauryliuk and their colleagues found an explanation. They showed that some SASs are components of so-called toxin-antitoxin (TA) systems.

Read more: Vasili Hauryliuk (MIMS) and Gemma Atkinson (UCMR) lead milestone paper in PNAS on new kind of...